The Paris Court of Appeal (“Court of Appeals”) has issued its ruling on damages in the Plavix follow-on action brought by France’s national health insurance fund (the “CNAM”) against Sanofi.[1] More than a decade after the French Competition Authority (“FCA”) found that Sanofi had engaged in disparagement practices constituting an abuse of dominant position, the Court awarded the CNAM €150.7 million, reflecting the long-term impact of Sanofi’s conduct. The judgment highlights the magnitude of potential damages in follow-on actions and illustrates how French courts evaluate long-lasting effects and the full-compensation principle.